MİYOKARDİT

Abstract

Miyokardit, değişik nedenler ile meydana gelen inflamatuar yanıta ikincil kalbin miyokart tabakasını etkileyen bir hastalıktır. En yayın sebebi virüslerdir. Klinik seyri genellikle kendini sınırlayıcı ve selimdir, ancak klinik kötüleşme-hemodinamik durumun bozulması da mümkündür. Bu çalışmada biz 2000-2011 yılları arasında literatürü gözden geçirerek miyokardit tanısı, klinik seyri ve tedavi seçeneklerinin güncellemeyi amaçladık.

Keywords

• kalp; inflamasyon; miyokardit

Saglik Bil Derg Cilt:1 Sayı:2 Ağustos 2012 80

Abstract

Myocarditis is disorder effecting myocardium of the heart secondary to inflammatory response caused by various reasons. The most common cause of myocarditis is viruses. Clinical course is usually self-limiting and benign; however, clinical deterioration, which impairs hemodynamic state, is also possible. In this study, we presented updated diagnosis, clinical course and treatment options of myocarditis by review of literature between 2000 and 2011.

Keywords

• heart; inflammation; myocarditis

References

1. 1. Feldman AM, McNamara D. Myocarditis. N Engl J Med. 2000; 343(19): 1388–98
2. 2. Blauwet LA, Cooper LT. Myocarditis. Prog Cardiovasc Dis. 2010;52(4):274-88
3. 3. Brady WJ, Ferguson JD, Ullman EA, Perron AD. Myocarditis: emergency department recognition and management. Emerg Med Clin North Am. 2004;22(4):865-85
4. 4. Punja M, Mark DG, McCoy JV, Javan R, Pines JM, Brady W. Electrocardiographic manifestations of cardiac infectious-inflammatory disorders. Am J Emerg Med.2010;28(3): 364-77
5. 5. Felker GM, Thompson RE, Hare JM, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med. 2000;342(15):1077-84
6. 6. Liu PP, Mason JW. Advances in the understanding of myocarditis. Circulation 2001; 104(9): 1076-82
7. 7. Kyto V, Saraste A, Voipio-Pulkki LM, Saukko P. Incidence of fatal myocarditis: a population-based study in Finland. Am J Epidemiol. 2007;165(5):570-74
8. 8. Fabre A, Sheppard MN. Sudden adult death syndrome and other non-ischaemic causes of sudden cardiac death. Heart 2006;92(3):16-20

9. 9. Nugent AW, Daubeney PE, Chondros P, et al.; National Australian Childhood Cardiomyopathy Study. The epidemiology of childhood cardiomyopathy in Australia. N Engl J Med. 2003;348(17):1639-46
10. 10. Schwartz J, Sartini D, Huber S. Myocarditis susceptibility in female mice depends upon ovarian cycle phase at infection. Virology 2004;330(1):16-23
11. 11. Kuhl U, Pauschinger M, Noutsias M, et al. High prevalence of viral genomes and multiple viral infections in the myocardium of adults with “idiopathic” left ventricular dysfunction. Circulation 2005;111(7):887-93
12. 12. Bowles NE, Ni J, Kearney DL, et al. Detection of viruses in myocardial tissues by polymerase chain reaction. Evidence of adenovirus as a common cause of myocarditis in children and adults. J Am Coll Cardiol. 2003;42(3):466-72
13. 13. Matsumori A . Hepatitis C virus infection and cardiomyopathies.Circ Res. 2005;96(2):148-50
14. 14. Ellis CR, Di Salvo T. Myocarditis: basic and clinical aspects. Cardiol Rev.2007;15(4):170-7
15. 15. Magnani JW, Dec GW. Myocarditis: current trends in diagnosis and treatment. Circulation 2006;113(6):876-90
16. 16. Liu PP, Schultheiss HP. Myocarditis. In:. Braunwald’s heart disease: a textbook of cardiovascular medicine. (Volume 2). Libby P, Braunwald E (Ed.), W. B. Saunders, Philadelphia, 2008;1784-5
17. 17. Sheppard R, Bedi M, Kubota T, et al. Myocardial expression of fas and recovery of left ventricular function in patients with recent-onset cardiomyopathy. J Am Coll Cardiol. 2005;46(6):1036-42
18. 18. Nishii M, Inomata T, Takehana H, et al.Serum levels of interleukin-10 on admission as a prognostic predictor of human fulminant myocarditis. J Am Coll Cardiol. 2004;44(6):1292-7
19. 19. Kuhl U, Pauschinger M, Seeberg B, et al. Viral persistence in the myocardium is associated with progressive cardiac dysfunction. Circulation 2005;112(13):965-70
20. 20. Felker GM, Boehmer JP, Hruban RH, et al. Echocardiographic findings in fulminant and acute myocarditis. J Am Coll Cardiol 2000;36(1):227–232
21. 21. Mahrholdt H, Goedecke C, Wagner A, et al. Cardiovascular magnetic resonance assessment of human myocarditis: a comparison to histology and molecular pathology. Circulation 2004;109(10):1250–8
22. 22. Liu PP,Yan AT.Cardiovascular magnetic resonance for the diagnosis of acute myocarditis: prospects for detecting myocardial inflammation. J Am Coll Cardiol 2005;45(11):1823–25
23. 23. Abdel-Aty H, Boye P, Zagrosek A, et al. Diagnostic performance of cardiovascular magnetic resonance in patients with suspected acute myocarditis: comparison of different approaches. J Am Coll Cardiol. 2005;45(11):1815-22
24. 24. Friedrich MG, Sechtem U, Schulz-Menger J, et al.; International Consensus Group on Cardiovascular Magnetic Resonance in Myocarditis.Cardiovascular magnetic resonance in myocarditis: A JACC White Paper. J Am Coll Cardiol. 2009;53(17):1475-87
25. 25. Childs H, Friedrich MG. Cardiovascular magnetic resonance imaging in myocarditis. Prog Cardiovasc Dis. 2011;54(3):266-75
26. 26. Wassmuth R, Schulz-Menger J. Cardiovascular magnetic resonance imaging of myocardial inflammation. Expert Rev Cardiovasc Ther. 2011;9(9):1193-201.
27. 27. Jiji RS, Kramer CM. Cardiovascular magnetic resonance: applications in daily practice. Cardiol Rev. 2011;19(5):246-54.
28. 28. Kindermann I, Kindermann M, Kandolf R, et al.Predictors of outcome in patients with suspected myocarditis. Circulation. 2008;118(12),e-493
29. 29. Cooper LT, Baughman KL, Feldman AM,et al. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology,and the European Society of Cardiology. Circulation. 2007;116(19):2216-33
30. 30. Cooper LT: Myocarditis. NEJM. 2009;360(15):1526-38
31. 31. Chen F, Shannon K, Ding S, et al. HIV type 1 glycoprotein 120 inhibits cardiac myocyte contraction. AIDS Res Hum Retroviruses. 2002;18(11):777-84
32. 32. Mahfoud F, Gärtner B, Kindermann M, Ukena C, Gadomski K, Klingel K. Virus serology in patients with suspected myocarditis: utility or futility? Eur Heart J. 2011;32(7):897-903.
33. 33. Yajima T. Viral myocarditis: potential defense mechanisms within the cardiomyocyte against virus infection. Future Microbiol. 2011;6(5):551-66
34. 34. Rassi Jr A, Rassi A, Little WC, et al. Development and validation of a risk score for predicting death in Chagas' heart disease. N Engl J Med. 2006;355(8):799-808
35. 35. Cooper LT: Giant cell myocarditis: diagnosis and treatment. Herz 2000;25(3):291–8
36. 36. McCarthy RE, Boehmer JP, Hruban RH, et al: Long-term outcome of fulminant myocarditis as compared with acute (nonfulminant) myocarditis. N Engl J Med. 2000;342(10):690-5
37. 37. Cooper LT, Zehr KJ. Biventricular asist device placement and immunosuppression as therapy for necrotizing eosinophilic myocarditis. Nat Clin Pract Cardiovasc Med. 2005;2(10):544-8
38. 38. Fuse K, Chan G, Liu Y, et al. Myeloid differentiation factor-88 plays a crucial role in the pathogenesis of coxsackievirus B3 induced myocarditis, and influences type I interferon production. Circulation. 2005;112(15):2276-85
39. 39. Farrar DJ, Holman WR, McBride LR, et al.Long-term follow-up of Thoratec ventricular assist device bridge-to-recovery patients successfully removed from support after recovery of ventricular function. J Heart Lung Transplant. 2002;21(5):516-21
40. 40. Chen YS, Yu HY. Choice of mechanical support for fulminant myocarditis: ECMO vs. VAD? Eur J Cardiothorac Surg. 2005;27(5):931-2
41. 41. Schultheiss HP, Kühl U, Cooper LT. The management of myocarditis. Eur Heart J. 2011;32(21):2616-25
42. 42. Wang YX, da Cunha V, Vincelette J, et al. Antiviral and myocyte protective effects of murine interferon-beta and -{alpha}2 in coxsackievirus B3-induced myocarditis and epicarditis in Balb/c mice. Am J Physiol. 2007;293(1):H69-76
43. 43. Horwitz MS, La Cava A, Fine C, Rodriguez E, Ilic A, Sarvetnick N: Pancreatic expression of interferon-gamma protects mice from lethal coxsackievirus B3 infection and subsequent myocarditis. Nat Med. 2000;6(6):693-97
44. 44. Kuhl U, Pauschinger M, Schwimmbeck PL, et al.Interferon-beta treatment eliminates cardiotropic viruses and improves left ventricular function in patients with myocardial persistence ofviral genomes and left ventricular dysfunction. Circulation. 2003;107(22): 2793-8
45. 45. McNamara DM, Holubkov R, Starling RC, et al. Controlled trial of intravenous immune globulin in recent-onset dilated cardiomyopathy. Circulation 2001;103(18):2254-9